Pemphigoid Oral: Symptoms, Diagnosis, and Management

Oral mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease in which the immune system attacks the tissue lining the mouth, producing painful sores, fragile blisters, and chronically inflamed gums that can persist for months or years if left untreated.¹ The condition can also affect the eyes, nose, throat, and genitals, but the mouth is one of the most common starting points. Getting the right diagnosis is often frustratingly slow, and management requires a careful, staged approach that balances controlling inflammation with minimizing side effects from the drugs used to do it.

What Oral Pemphigoid Looks and Feels Like

The hallmark symptom is desquamative gingivitis, a term that simply means the gums look raw, red, and peeling. Unlike the redness you might see with ordinary gum disease, this version is widespread, does not respond to improved brushing or dental cleanings, and tends to hurt. The tissue is so fragile that even gentle contact from eating or tooth-brushing can cause the top layer to slough off, leaving exposed, bleeding patches.

Blisters and vesicles can form on the gums, inner cheeks, palate, or tongue. They are often small and short-lived because the thin oral lining ruptures easily, so you may never see an intact blister. Instead, what you notice are shallow, irregular erosions and ulcers that take weeks to heal. Swallowing can become painful when lesions extend to the soft palate or throat, and some people report a chronic burning sensation that makes spicy or acidic foods intolerable.

Scarring is an important distinction between pemphigoid and some other oral blistering conditions. Oral MMP can produce scar tissue, particularly in areas where blisters recur. In the mouth, scarring may cause tightening of the tissue around the gums or limited mouth opening over time. This cicatrizing tendency is the same process that, when it happens in the eyes, can threaten vision.

Why It Takes So Long to Get a Diagnosis

One of the most frustrating aspects of oral pemphigoid is the gap between when symptoms appear and when the condition is correctly identified. A study at a regional tertiary center in Japan found that the median total delay from first symptoms to definitive diagnosis was ten months. Strikingly, most of that delay was professional rather than patient-driven: patients typically sought care within about a month, but it took a median of seven additional months for clinicians to reach the right diagnosis.² A broader review of oral autoimmune blistering diseases found an average diagnostic delay of about eight months.³

Why the bottleneck? For one thing, the condition is uncommon enough that many dentists and general practitioners have seen few or no cases. In the Japanese cohort, oral symptoms were the first sign in roughly three-quarters of patients, and dentistry was the most common first specialty consulted. Yet at that first visit, over half the patients were initially told they had gingivitis, periodontitis, or stomatitis, and autoimmune blistering disease was suspected in only about one in eight cases.² The early appearance of oral MMP genuinely does overlap with more common conditions, making it easy to miss without a biopsy.

That delay matters. Ongoing, uncontrolled inflammation can lead to scarring both in the mouth and at other mucosal sites. If the disease has already spread to the eyes by the time it is caught, irreversible damage may have begun. Anyone with persistent, unexplained gum erosions that fail to improve with standard periodontal treatment should push for a biopsy and immunofluorescence testing rather than waiting through repeated rounds of antibiotics or mouthwashes.

How the Diagnosis Is Confirmed

A clinical exam alone is not enough to confirm oral pemphigoid, because several other conditions, including pemphigus vulgaris and erosive oral lichen planus, can cause very similar-looking lesions. The diagnostic gold standard is a combination of routine biopsy and direct immunofluorescence (DIF).⁴

A standard biopsy taken from the edge of a blister or erosion is examined under the microscope. In pemphigoid, you see a split at the junction between the surface layer and the deeper tissue, with the entire surface layer lifting away in one piece. This subepithelial split is a clue, but it is not unique to pemphigoid. The DIF biopsy, taken from tissue next to a lesion rather than from the lesion itself, looks for antibodies and complement proteins deposited in a specific pattern along the basement membrane zone. A continuous, linear band of IgG, IgA, or C3 at that zone is the fingerprint of pemphigoid.⁵⁶

Blood tests can offer supporting evidence. An ELISA test that detects circulating antibodies against a protein called BP180 is available, but its sensitivity in oral-only pemphigoid is modest, around 50%, meaning it misses about half of true cases. Its specificity is better, at roughly 83%, so a positive result is meaningful.⁴ A separate study found that patients whose BP180 antibody levels at diagnosis were above a specific threshold had more severe disease and were more likely to relapse after treatment.⁷ So while a blood test alone cannot confirm or rule out oral pemphigoid, higher antibody levels can help clinicians gauge how aggressively to treat.

What Pemphigoid Gets Confused With

Pemphigus vulgaris is the main look-alike. Both cause oral erosions, both can present as desquamative gingivitis, and both require immunofluorescence to diagnose definitively. The key difference under the microscope is where the tissue splits: pemphigoid splits at the basement membrane (below the surface layer), while pemphigus splits within the surface layer itself, producing loose, rounded cells called acantholytic keratinocytes. Advanced imaging techniques such as reflectance confocal microscopy can sometimes distinguish the two non-invasively by spotting these different splitting patterns in real time.⁸

Erosive lichen planus is another condition that mimics oral pemphigoid. It too produces sore, red gums and eroded patches. Lichen planus often shows white, lacy streaks (Wickham striae) alongside the erosions, which can be a visual clue, but not all cases display them. Again, biopsy and DIF are what separate the diagnoses reliably.

What Is Happening Beneath the Surface

In oral pemphigoid, the immune system produces antibodies that attack structural proteins anchoring the surface tissue to the layer beneath it. The main target in about 80% of patients is a protein called type XVII collagen (also known as BP180). In roughly 10 to 20% of patients, the target is a different protein called laminin 332.⁹ When antibodies bind to these proteins, they trigger an inflammatory cascade that damages the anchoring zone and causes the tissue layers to separate, forming blisters.

Which protein is targeted matters clinically. Anti-laminin 332 pemphigoid has been linked to a somewhat higher risk of associated malignancy compared to the BP180 form, so identifying the target antigen through specialized testing can influence how thoroughly a patient is screened for other conditions. There is also a genetic component: certain HLA class II alleles, including DQB1*0301, have been associated with susceptibility to MMP and may influence which autoantibodies a patient develops.¹⁰

Why the Eyes Need Checking

Even when pemphigoid starts in the mouth, it does not always stay there. Ocular involvement occurs in about 70% of all MMP cases and is the most feared complication because unchecked inflammation can scar the conjunctiva (the clear membrane lining the inside of the eyelids), damage the cornea, and lead to visual impairment or blindness.¹¹¹²

The good news is that patients whose disease stays confined to the oral mucosa generally have a more benign course. The bad news is that ocular disease, when present, tends to be more resistant to treatment and more prone to progressive scarring.⁶ This is why current practice recommends that every patient diagnosed with oral MMP be referred for an ophthalmologic examination, even if they have no eye symptoms. Early eye involvement can be subtle, with chronic redness or mild irritation that a patient might write off as dry eyes or allergies. By the time scarring is visible, the damage is harder to reverse.

The nose, throat, larynx, and genital mucosa can also be affected. Nasal involvement sometimes presents as recurrent nosebleeds or crusting; laryngeal involvement can cause hoarseness. A multidisciplinary team, often including a dermatologist or oral medicine specialist, an ophthalmologist, and an ear-nose-throat specialist, gives the best chance of catching disease at all affected sites.

Treatment for Mild to Moderate Oral Disease

Treatment is staged according to severity and which sites are involved. For disease limited to the mouth with relatively mild symptoms, topical therapy is the first step. High-potency corticosteroids applied directly to the gums and affected areas can reduce inflammation and promote healing. A practical challenge is keeping the medication in contact with wet oral tissue long enough to work. One approach that has shown good results uses custom-fitted trays, similar to fluoride trays, that hold the steroid gel against the gums for a sustained period.¹³ Topical tacrolimus, a non-steroidal immunosuppressant, is sometimes used as an alternative when steroid side effects become a concern or when steroid response is incomplete.

Gentle oral hygiene is not a treatment per se, but it substantially influences comfort and outcomes. Using a soft-bristled toothbrush, avoiding abrasive toothpastes containing sodium lauryl sulfate, and rinsing with bland mouthwashes can reduce trauma to fragile tissue. Some clinicians prescribe chlorhexidine rinses short-term to control secondary bacterial infection in eroded areas.

Systemic Treatment for Severe or Spreading Disease

When the disease is more extensive, involves the eyes or other mucosal sites, or fails to respond adequately to topical therapy, systemic immunosuppression becomes necessary. The most commonly used first-line systemic agent is dapsone, an anti-inflammatory drug with a long track record in blistering diseases. Dapsone is often combined with a low dose of oral corticosteroids (typically prednisolone or prednisone) while waiting for the slower-acting agent to take effect.

For patients who do not respond to dapsone or cannot tolerate it, mycophenolate mofetil is a frequently chosen alternative. A case series reported safe and successful control of significant oral MMP-related inflammation using a combination of mycophenolate mofetil, dapsone, and prednisolone at relatively low doses.¹⁴ Azathioprine and methotrexate are other options in the same general category. All of these immunosuppressants require monitoring through regular blood tests because they can affect liver function, blood counts, or kidney function over time.

The goal of systemic therapy is to bring the disease into remission, meaning no new blisters or erosions, and then gradually taper the medication to the lowest dose that keeps the disease quiet. Some patients can eventually stop treatment entirely; others need a low maintenance dose for years.

Biologic Therapy for Refractory Cases

Rituximab, a biologic drug that depletes a specific type of immune cell (B cells), has become an increasingly important option for patients with pemphigoid that does not respond to conventional immunosuppressants or whose disease involves the eyes with progressive scarring. In one large retrospective study of 109 patients treated with rituximab for MMP, the drug was used for cases that had failed multiple prior therapies.¹⁵

Another study specifically examined rituximab combined with intravenous immunoglobulin (IVIG) for pemphigoid-associated cicatrizing conjunctivitis. Over 93% of patients showed a positive response, with roughly a third achieving steroid-free remission.¹⁶ These are encouraging numbers, but rituximab carries its own risks, including increased susceptibility to infection due to immune suppression. It is typically reserved for patients whose disease threatens sight or who have failed safer agents.

Drug-Triggered Pemphigoid

Not every case of pemphigoid arises spontaneously. Certain medications can trigger a form that is clinically and immunologically very similar to the idiopathic (no known cause) version. A systematic review identified 89 drugs implicated in drug-associated bullous pemphigoid, with the strongest evidence pointing to gliptins (a class of diabetes drugs), PD-1/PD-L1 checkpoint inhibitors (used in cancer immunotherapy), loop diuretics, and penicillin-based antibiotics.¹⁷

This is worth knowing for two reasons. First, if you are diagnosed with oral pemphigoid and you happen to be taking one of these medications, your doctors should consider whether the drug could be a contributing factor. In some cases, stopping or switching the offending medication leads to improvement, although full resolution may still take time and additional treatment. Second, the rapid expansion of checkpoint inhibitor use in oncology has made this a growing clinical scenario. Patients on these cancer drugs who develop new blistering lesions in the mouth need prompt evaluation.

Living with Oral Pemphigoid

Chronic oral blistering disease affects quality of life in ways that go well beyond the physical symptoms. Eating, drinking, and speaking can be painful during flares. Social eating becomes stressful. Some patients avoid dental visits out of fear that even a cleaning will trigger a flare, which paradoxically allows dental disease to worsen. Research on the closely related condition bullous pemphigoid found that the majority of patients reported high disturbance ratings for their symptoms and the downstream impacts on daily functioning, with most salient symptoms scoring above 7.5 out of 10 on a disturbance scale.¹⁸ Oral pemphigoid carries a comparable burden, compounded by the fact that it can feel invisible to others since the lesions are hidden inside the mouth.

Finding a dentist or dental hygienist who understands autoimmune oral conditions can make a real difference. Atraumatic cleaning techniques, shorter appointment intervals to prevent plaque buildup, and coordinated care with your prescribing specialist help keep the mouth as healthy as possible without triggering flares. Support communities, whether online or through dermatology patient organizations, offer practical tips and emotional validation that can be harder to find from clinicians who see only a handful of cases per year.

Monitoring and Long-Term Outlook

Oral pemphigoid is a chronic disease, but “chronic” does not automatically mean “lifelong active disease.” Many patients achieve remission with treatment, and some stay in remission after medications are tapered. Others experience a relapsing-remitting pattern, with flares triggered by stress, illness, dental procedures, or for no identifiable reason. Higher circulating BP180 antibody levels at diagnosis have been associated with a greater likelihood of relapse after achieving remission, suggesting these patients may benefit from closer follow-up.⁷

Ongoing monitoring should include regular eye exams even when the disease appears confined to the mouth, periodic blood work if you are on systemic immunosuppressants, and attention to any new sites of involvement such as nasal crusting or skin blisters. Because the oral mucosa heals more readily than some other mucosal sites, the prognosis for patients whose disease stays in the mouth is generally favorable compared to those with multi-site or ocular disease.⁶ The most important thing you can do is stay engaged with a care team that knows the condition and respond quickly if symptoms change or new sites become involved.

1
PubMed. Oral mucous membrane pemphigoid: updates in diagnosis and management
2
PubMed. The Diagnostic Journey of Mucous Membrane Pemphigoid: Referral Pathways and Diagnostic Delay at a Regional Tertiary Dermatology Center in Japan
3
PubMed. Diagnostic delay in autoimmune oral diseases
4
PubMed. Evaluation of BP180-NC16A ELISA in exclusive oral pemphigoid diagnosis. A comparative study
5
PubMed Central. Diagnostic value of direct immunofluorescence in oral mucous membrane pemphigoid: a retrospective study
6
Oral Surgery, Oral Medicine, Oral Pathology. Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)
7
Applied Sciences. Elevated BP180 ELISA at Diagnosis Correlates with Disease Severity and Relapse in Oral Mucous Membrane Pemphigoid: Preliminary Results from a Retrospective Monocentric Italian Study
8
PubMed. Reflectance confocal microscopy as a new tool in the in vivo evaluation of desquamative gingivitis: patterns in mucous membrane pemphigoid, pemphigus vulgaris and oral lichen planus
9
PubMed Central. Autoimmunity against laminin 332
10
PubMed. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid
11
PubMed Central. Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment
12
PubMed. Evaluation of mucous membrane pemphigoid with ocular involvement in young patients
13
Oral Surgery, Oral Medicine, Oral Pathology. Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid
14
PubMed. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series
15
PubMed Central. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients
16
AJO International. Rituximab and intravenous immunoglobulin in the treatment of cicatrizing conjunctivitis associated with pemphigoid
17
PubMed Central. A Systematic Review of Drug-Induced Pemphigoid
18
Dermatology and Therapy. Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts